抗体偶联药物在妇科恶性肿瘤中的临床应用:现有药物与新兴疗法综述
综述总结抗体偶联药物(ADC)在妇科恶性肿瘤中的应用,包括FDA已批准的mirvetuximab soravtansine、tisotumab vedotin和trastuzumab deruxtecan及相关进行中的临床试验(含TROP2 ADC)。同时概述PD-1联合化疗、放化疗联合帕博利珠单抗及PARP抑制剂/贝伐珠单抗维持治疗在晚期子宫内膜癌、宫颈癌和卵巢癌中的生存获益。
要点
- ADC在妇科恶性肿瘤中具活性,毒性谱与其构造相关。
- FDA已批准用于妇科肿瘤的ADC包括mirvetuximab soravtansine、tisotumab vedotin和trastuzumab deruxtecan。
- 不良事件缓解策略、生物标志物发现和序贯治疗对利用ADC治疗窗至关重要。
核心结论
- ADC是一类在妇科恶性肿瘤中具活性的创新药物,其独特毒性谱源于ADC构造,不良事件缓解策略、生物标志物发现和序贯治疗对成功利用其治疗窗至关重要。
研究设计与样本
- 综述,讨论ADC在妇科癌症中的应用,包括FDA已批准药物及相关进行中的临床试验(含TROP2 ADC)。
主要发现
- 抗PD-1免疫治疗联合全身化疗在晚期子宫内膜癌和PD-L1+复发/转移性宫颈癌中报告了显著总生存获益。
- FIGO III-IVA期局部晚期宫颈癌患者(无论PD-L1状态)接受放化疗联合帕博利珠单抗后帕博利珠单抗维持治疗也带来生存获益。
- 新诊断晚期卵巢癌对初始化疗有反应者,根据胚系和体细胞突变分析使用PARP抑制剂和/或贝伐珠单抗维持治疗可改善无进展生存期。
- 肿瘤异质性、获得性耐药和不良事件限制长期疗效。
局限性
- 肿瘤异质性、获得性耐药和不良事件限制长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With significant overall survival benefits reported in several phase 3 randomized clinical trials, the integration of anti-PD-1 immunotherapy with systemic chemotherapy has transformed the therapeutic landscape in advanced endometrial cancer and PD-L1+ recurrent/metastatic cervical cancer. For patients with FIGO stage III-IVA locally advanced cervical cancer, irrespective of PD-L1 status, chemoradiation plus pembrolizumab followed by maintenance pembrolizumab also confers a survival benefit. For newly diagnosed advanced ovarian cancer responding to primary systemic chemotherapy, maintenance therapy using PARP inhibitors and/or bevacizumab according to germline and somatic mutational analysis have been demonstrated to improve progression-free survival. Tumor heterogeneity, acquired drug resistance, and adverse events limit long-term effectiveness. Antibody-drug conjugates (ADCs) represent an innovative new class of medicines with activity in gynecologic malignancies and distinct toxicity profiles attributable to ADC construction. Adverse event mitigation strategies, biomarker discovery, and sequencing are paramount in successfully exploiting the therapeutic window provided by these novel compounds. This review discusses the application of ADCs in gynecologic cancers, including the current FDA-approved drugs mirvetuximab soravtansine, tisotumab vedotin, and trastuzumab deruxtecan, as well as relevant ongoing clinical trials, including TROP2 ADCs.
引用
- Bujnak AC, Solaru SA, Tewari K, et al. Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics. Gynecol Oncol. 2025. PMID: 40139025. doi:10.1016/j.ygyno.2025.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。